Natixis Advisors, L.P. Roivant Sciences Ltd. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 69,535 shares of ROIV stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,535
Previous 36,433
90.86%
Holding current value
$1.12 Million
Previous $368,000
113.04%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ROIV
# of Institutions
362Shares Held
456MCall Options Held
8.36MPut Options Held
760K-
Sb Investment Advisers (Uk) LTD London, X060MShares$966 Million5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$720 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$634 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$570 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$552 Million1.22% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $11.4B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...